Immunoglobulin Fragments

Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.

Also Known As:

Fragment, Antibody; Fragment, Ig; Fragment, Immunoglobulin; Fragments, Antibody; Fragments, Ig; Fragments, Immunoglobulin; Antibody Fragment; Antibody Fragments; Ig Fragment; Ig Fragments; Immunoglobulin Fragment

Networked: 976 relevant articles (68 outcomes, 94 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Fc Fragments: 295
        Immunoglobulin Idiotypes: 67
        DT390-anti-CD3sFv: 1
        Fd immunoglobulins: 1
        Fv-interferon gamma: 1
        immunotoxin 4D5MOCB-ETA: 1
        CD3fos-F(ab')2
        Fch fragments
        human MFE-23 protein
        igercine
        immunoglobulin Fv
        immunoglobulin G (285-292)
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Fc Fragments: 295
        Immunoglobulin Idiotypes: 67
        DT390-anti-CD3sFv: 1
        Fd immunoglobulins: 1
        Fv-interferon gamma: 1
        immunotoxin 4D5MOCB-ETA: 1
        CD3fos-F(ab')2
        Fch fragments
        human MFE-23 protein
        igercine
        immunoglobulin Fv
        immunoglobulin G (285-292)
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Fc Fragments: 295
        Immunoglobulin Idiotypes: 67
        DT390-anti-CD3sFv: 1
        Fd immunoglobulins: 1
        Fv-interferon gamma: 1
        immunotoxin 4D5MOCB-ETA: 1
        CD3fos-F(ab')2
        Fch fragments
        human MFE-23 protein
        igercine
        immunoglobulin Fv
        immunoglobulin G (285-292)
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976

Experts

1.	Neri, Dario: 26 articles (01/2021 - 07/2002)
2.	Wu, Anna M: 20 articles (01/2020 - 12/2003)
3.	Olafsen, Tove: 10 articles (01/2017 - 09/2002)
4.	Shively, John E: 9 articles (09/2017 - 09/2002)
5.	Yazaki, Paul J: 9 articles (09/2017 - 12/2003)
6.	Colcher, David: 8 articles (09/2017 - 08/2004)
7.	Kontermann, Roland E: 7 articles (10/2020 - 10/2008)
8.	Bremer, Edwin: 7 articles (01/2019 - 04/2006)
9.	Helfrich, Wijnand: 7 articles (01/2019 - 04/2006)
10.	Wels, Winfried S: 7 articles (01/2017 - 03/2005)

Related Diseases

1.	Neoplasms (Cancer) 08/01/1997 - "The utility of radiolabeled antibody fragments has been improved by the development of site-specific labeling methods and by the advent of the 'minibody', an engineered fragment that has proved to be highly successful for tumor imaging in mice." 07/01/1999 - "By virtue of the rapid clearance of the antibody fragment from the circulation, tumor-to-blood ratios of 1.9, 3.7, and 11.8 were obtained at 3, 5, and 24 hours, respectively. " 01/01/2023 - "Altogether, 89Zr-DFO-Miltuximab appears to be an effective immuno-PET imaging agent for detecting GPC-1positive tumors such as GBM and the current results support utility of the Fc containing whole mAb format over smaller antibody fragments for this target." 01/01/2019 - "Recent advantages in antibody engineering allowed to produce different types of antibody fragments with improved structure and properties for efficient elimination of tumor cells. " 05/01/2012 - "A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio."
2.	Poisoning 09/01/1985 - "A report is presented of the clinical experience in the treatment of severe digitalis poisoning in nine young children aged 1 month to 4 years with digitalis antibody fragments (Fab). " 09/01/2014 - "Digoxin-specific antibody fragments (digoxin-Fab) are widely regarded as a safe and effective treatment for the management of acute and chronic digoxin poisoning. " 11/01/2012 - "The consumption of coconut crab in New Caledonia should be avoided even though the first of the two cases reported suggests that digoxin-specific Fab antibody fragments can be effective in the treatment of life-threatening poisoning caused by the ingestion of this crustacean." 01/01/2021 - "Dose and efficacy of repeated administrations of digoxin-specific antibody fragments: Case report of foxglove poisoning." 01/01/2022 - "Monitoring free digoxin serum concentrations after injection of digoxin-specific antibody fragments in a man with chronic digoxin poisoning."
3.	Diarrhea 01/01/2016 - "We assessed the efficacy of two VP6-specific llama-derived heavy chain antibody fragments (VHH) -2KD1 and 3B2- as an oral prophylactic and therapeutic treatment against RVA-induced diarrhea in a neonatal mouse model inoculated with virulent murine RVA (ECw, G16P[16]I7). " 12/01/2006 - "Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea." 01/01/2013 - "Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea." 10/01/2008 - "Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice." 10/01/2013 - "We assessed the efficacy of a llama-derived, heavy-chain antibody fragment called anti-rotavirus protein (ARP1), in modifying the severity and duration of diarrhea in male infants with rotavirus infection. "
4.	Macular Degeneration (Age-Related Maculopathy) 09/01/2010 - "VEGF antibody fragments have been approved for age-associated macular degeneration (AMD) in different countries and have proved to be safe and effective. " 12/01/2021 - "Novel Dual-Targeting Antibody Fragment IDB0062 Overcomes Anti-Vascular Endothelial Growth Factor Drug Limitations in Age-Related Macular Degeneration." 06/01/2005 - "Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration." 03/01/2011 - "Ranibizumab (Lucentis), a humanised antibody fragment that inhibits vascular endothelial growth factor (VEGF)-A, is widely used for the treatment of neovascular age-related macular degeneration (NV-AMD). " 05/01/2016 - "Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study."
5.	Rheumatoid Arthritis 01/01/2019 - "Antibody fragment F8-mediated interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). " 01/01/2022 - "Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study." 05/01/2003 - "Celltech Group plc (formerly Celltech Chiroscience), in collaboration with Pfizer Inc (formerly Pharmacia Corp), is developing CDP-870, a polyethylene glycol (PEG)ylated anti-TNF antibody fragment, for the potential treatment of certain autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Crohn's disease (CD). " 02/16/2023 - "CTLA4Ig is a dimeric fusion protein of the extracellular domain of cytotoxic T-lymphocyte protein 4 (CTLA4) and an Fc (Ig) fragment of human IgG1 that is approved for treating rheumatoid arthritis. " 10/28/2020 - "Certolizumab pegol is a Fab' antibody fragment for treatment of rheumatoid arthritis and Crohn's disease which is conjugated to a 40 kDa PEG molecule in order to increase the protein half-life. "

Related Drugs and Biologics

1.	Digoxin (Digitek)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Proteins (Proteins, Gene)
4.	Antibodies
5.	Peptides (Polypeptides)
6.	Immunoglobulin G (IgG)
7.	Ranibizumab (Lucentis)
8.	Cytokines
9.	Antigens
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Intravitreal Injections
4.	Radioimmunotherapy
5.	Photochemotherapy (Photodynamic Therapy)